| Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 |
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations |
globenewswire.com |
2025-05-14 13:30:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates |
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the first quarter ended March 31, 2025, and provided corporate updates. |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) |
FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. |
globenewswire.com |
2025-05-02 20:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference |
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET. |
globenewswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround |
Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-04-07 14:46:25 |
Czytaj oryginał (ang.) |
| Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) |
Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-04-03 14:35:42 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) |
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy |
Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-26 15:00:29 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates |
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates. |
globenewswire.com |
2025-03-20 18:05:00 |
Czytaj oryginał (ang.) |
| This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street |
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals (TERN -3.86%). |
fool.com |
2025-03-09 12:03:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) |
FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 24, 2025 an equity inducement award to Andrew Gengos, the Company's new chief financial officer, under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity award was approved by the Compensation Committee of the Company's Board of Directors and the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to Mr. Gengos' acceptance of employment with Terns. |
globenewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference |
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 |
globenewswire.com |
2025-02-25 10:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer |
Seasoned public company CFO with 25 years of leadership experience in biotech Seasoned public company CFO with 25 years of leadership experience in biotech |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors |
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise |
globenewswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:00 p.m. ET. |
globenewswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) |
FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns. |
globenewswire.com |
2025-02-03 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference |
FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT. |
globenewswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) |
FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns. |
globenewswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| Terns's stock soars as analysts cheer leukemia data — and predict more gains |
The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill. |
marketwatch.com |
2024-12-04 15:18:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals price target raised to $20 from $17 at Oppenheimer |
Oppenheimer raised the firm's price target on Terns Pharmaceuticals to $20 from $17 and keeps an Outperform rating on the shares. Terns reported an interim update on TERN-701's Phase 1 study in chronic myeloid leukemia, providing "encouraging" three month efficacy and safety data that reinforce confidence surrounding its differentiated profile over existing tyrosine kinase inhibitors, the analyst tells investors in a research note. The firm believes TERN-701's emerging profile supports development in earlier-line settings, and its three-month performance strengthens its optimism surrounding longer-term major molecular response data, expected in Q4 of 2025. |
https://thefly.com |
2024-12-03 18:35:45 |
Czytaj oryginał (ang.) |
| Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial |
Terns Pharmaceuticals Inc.'s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia. |
marketwatch.com |
2024-12-03 10:01:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) |
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of December 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). |
globenewswire.com |
2024-12-02 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors |
Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience |
globenewswire.com |
2024-11-18 18:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) |
FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns. |
globenewswire.com |
2024-10-07 20:05:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst |
Terns Pharmaceuticals is developing TERN-601, an oral GLP-1R agonist, which showed a placebo-adjusted weight loss of 4.9% in a phase 1 trial for obesity treatment. The company plans to initiate a phase 2 study for TERN-601 in 2025, creating a significant catalyst opportunity for investors. The company is also developing TERN-701 for chronic myeloid leukemia, with interim phase 1 data expected in December 2024, offering another investment opportunity. |
seekingalpha.com |
2024-09-25 14:30:00 |
Czytaj oryginał (ang.) |
| This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments |
Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival. |
fool.com |
2024-09-18 14:07:00 |
Czytaj oryginał (ang.) |
| Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. |
Viking Therapeutics isn't the only weight loss biotech out there. Terns Pharmaceuticals just published some good phase 1 clinical trial data. |
fool.com |
2024-09-15 11:21:00 |
Czytaj oryginał (ang.) |
| Should You Invest in This Under-the-Radar Weight Loss Stock? |
Terns Pharmaceuticals' early-stage weight loss asset just reported positive clinical trial results. Even though it's showing some promise, Terns remains a risky bet. |
fool.com |
2024-09-15 10:09:00 |
Czytaj oryginał (ang.) |
| 1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More |
Terns Pharmaceuticals just reported some strong data from a phase 1 clinical trial. The data suggest that it might be able to make a highly tolerable weight loss drug. |
fool.com |
2024-09-14 14:12:00 |
Czytaj oryginał (ang.) |
| Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic |
The 'Undercovered' Dozen series highlights 12 undercovered stocks, providing investment ideas and sparking community discussion on their potential. Zach Bristow argues that Sylvamo Corporation offers a compelling risk/reward opportunity with reasonable valuations, shareholder-oriented management, and potential valuations up to $200/share. NuScale Power Corporation faces skepticism, according to George Theodosi, due to overhype and lack of US SMR projects, despite global interest in nuclear energy. |
seekingalpha.com |
2024-09-13 17:30:21 |
Czytaj oryginał (ang.) |
| Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares |
FOSTER CITY, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the closing of its previously announced underwritten public offering of 14,064,048 shares of its common stock, including 2,145,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock, at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are approximately $172.7 million. All of the securities were offered by Terns. |
globenewswire.com |
2024-09-12 23:00:00 |
Czytaj oryginał (ang.) |
| Terns Announces Pricing of Upsized $150.15 Million Public Offering |
FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be approximately $150.15 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 12, 2024, subject to customary closing conditions. All of the securities are being offered by Terns. |
globenewswire.com |
2024-09-11 02:50:00 |
Czytaj oryginał (ang.) |
| Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug |
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo. |
zacks.com |
2024-09-10 16:31:05 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive |
Terns Pharmaceuticals' TERN-601 shows impressive weight loss results in a phase 1 study, positioning TERN competitively in the obesity drug market. The commercial viability of TERN-601's manufacturing scalability could be an advantage over certain competitors like Novo Nordisk's Rybelsus. TERN has sufficient funds to support operations into 2026, and a recent $125M public offering could allow it to go further. |
seekingalpha.com |
2024-09-10 14:25:01 |
Czytaj oryginał (ang.) |
| Terns Announces Proposed Public Offering |
FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has commenced a proposed underwritten public offering of $125 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares and pre-funded warrants to be sold in the offering will be offered by Terns. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-09-09 20:01:00 |
Czytaj oryginał (ang.) |
| Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill |
Terns Pharmaceuticals' weight-loss pill has proved effective in a small trial, but still has much to prove before it can compete with blockbusters Zepbound and Wegovy. |
barrons.com |
2024-09-09 13:58:00 |
Czytaj oryginał (ang.) |
| Top 2 Health Care Stocks That May Collapse This Quarter |
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. |
benzinga.com |
2024-09-09 13:12:44 |
Czytaj oryginał (ang.) |